SCHEMBL19974443

SCHEMBL19974443

C[C@]1(COCc2ccccc2)C(OC(=O)c2ccccc2)O[C@H](COC(=O)c2ccccc2)[C@H]1OC(=O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
TDP1 Q9NUW8 2/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A3 Q01959 1/20 0.45
ALDH1A1 P00352 2/20 0.44
NT5E P21589 1/20 0.42
MAPT P10636 2/20 0.40
LMNA P02545 2/20 0.40
HPGD P15428 1/20 0.39
NPC1 O15118 1/20 0.38
POLB P06746 2/20 0.37
GAA P10253 2/20 0.37
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CHRNB2 P17787 2/20 0.37
CHRNA5 P30532 2/20 0.37
CHRNA7 P36544 2/20 0.37
CHRNA4 P43681 2/20 0.37
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974398 0.89 ALDH1A1 (0.49) KMT2ATDP1SLC6A2SLC6A3ALDH1A1
SCHEMBL21511255 0.85 ALDH1A1 (0.52) KMT2ATDP1SLC6A2SLC6A3ALDH1A1
SCHEMBL21082630 0.81 ALDH1A1 (0.52) KMT2ATDP1SLC6A2SLC6A3ALDH1A1
SCHEMBL19987360 0.81 ALDH1A1 (0.52) KMT2ATDP1SLC6A2SLC6A3ALDH1A1
SCHEMBL13184474 0.80 ALDH1A1 (0.51) KMT2ATDP1SLC6A2SLC6A3ALDH1A1
SCHEMBL21782410 0.80 ALDH1A1 (0.51) KMT2ATDP1SLC6A2SLC6A3ALDH1A1
SCHEMBL5682469 0.80 ALDH1A1 (0.51) KMT2ATDP1SLC6A2SLC6A3ALDH1A1
SCHEMBL13065704 0.80 ALDH1A1 (0.51) KMT2ATDP1SLC6A2SLC6A3ALDH1A1
SCHEMBL14853781 0.80 ALDH1A1 (0.51) KMT2ATDP1SLC6A2SLC6A3ALDH1A1
SCHEMBL13649108 0.80 ALDH1A1 (0.51) KMT2ATDP1SLC6A2SLC6A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11434255-B2 Nucleoside and nucleotide analogues bearing a quaternary all-carbon stereogenic center at the 2′ position and methods of use as a cardioprotective agent LCB PHARMA INC. (CA) 2022-09-06 US disclosed
EP-3512860-B1 NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT LCB PHARMA INC (CA) 2020-11-25 EP disclosed
EP-3512860-A1 NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT LCB Pharma Inc. (CA) 2019-07-24 EP disclosed
WO-2018049534-A1 NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT LCB PHARMA INC. (CA) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11434255-B2 Nucleoside and nucleotide analogues bearing a quaternary all-carbon stereogenic center at the 2′ position and methods of use as a cardioprotective agent TNNT2, NT5C2, PNP KMT2A 4054/4885TDP1 330/4885SLC6A2 1206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.